Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Reclassifying HFmrEF as a stable phenotype aims to reduce therapeutic inertia and GDMT underuse driven by heterogeneous labeling and clinician uncertainty. Pathobiologic overlap with HFrEF supports ...

A recent analysis based on pivotal RCTs in HFrEF showed that, compared with ACEI or ARB and beta-blocker therapy, treating patients with HFrEF with comprehensive disease-modifying medical therapy ...

prescription medicine Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients. Heart failure affects ...